Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alemtuzumab + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Royal Marsden NHS Foundation Trust
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Alemtuzumab + methylprednisolone is a combination therapy regimen evaluated by the Royal Marsden NHS Foundation Trust for the treatment of chronic lymphocytic leukemia (CLL), specifically targeting patients with p53 deletions or mutations. The regimen consists of the humanized monoclonal antibody alemtuzumab, which targets the CD52 antigen expressed on the surface of CLL cells, and high-dose methylprednisolone (HDMP), a potent corticosteroid that acts as a glucocorticoid receptor agonist. This combination is particularly significant because both agents induce apoptosis in CLL cells through mechanisms that are independent of the p53 pathway, providing a therapeutic alternative for patients who are typically resistant to conventional chemotherapy. The regimen was studied in clinical trials such as the UKCLL06 CAM-PRED trial and the National Cancer Research Institute CLL206 trial.
- Brand names
- Mabcampath
- Other names
- HDMP + alemtuzumabHigh-dose methylprednisolone and alemtuzumabalemtuzumab and methylprednisolone
02
Targets
GR (Glucocorticoid receptor)CD52 (CD52 Antigen)
Beyond the preview
Go deeper on alemtuzumab + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alemtuzumab + methylprednisolone.